age-related macular degeneration

OT-551 HCl is an NF-Κb inhibitor, a disubstituted hydroxylamine with antioxidant properties can be used for the treatment of cataracts and age-related macular degeneration and geographic atrophy (GA).

Methyl-4-oxoretinoate is a synthetic retinoid compound with anticancer compounds that can induce differentiation and apoptosis in cancer cells.Methyl-4-oxoretinoate is used in the treatment of acne, psoriasis, and other skin disorders.Methyl-4-oxoretinoate has the potential to be used in the treatment of a variety of ocular disorders such as age-related macular degeneration. related macular degeneration).

TG 100801 is a dual inhibitor of VEGFr2 and Src family (Src and YES) kinases and is a candidate compound for the treatment of age-related macular degeneration (AMD).

Palomid 529 (SG 00529) has been used in trials studying the treatment of Age-Related Macular Degeneration.

UBX1325, a Bcl-xL inhibitor, enhances apoptosis in senescent cells, serving as an effective anti-aging agent. It holds potential for age-related eye disease research, including diabetic macular oedema (DME), age-related macular degeneration (AMD), and diabetic retinopathy (DR) [1].

POT-4 acetate inhibits Complement C3 activation. POT-4 acetate can be used for studies about age-related macular degeneration.

Avacincaptad pegol (ARC1905), an anti-C5 RNA aptamer, prevents the cleavage of complement factor 5 (C5) into fragments C5a and C5b. It is currently under investigation for the treatment of age-related macular degeneration (AMD).

CEP dipeptide 1, a potent angiogenic compound, exhibits robust activity in promoting angiogenesis. This compound is specifically implicated in the pathogenesis of age-related macular degeneration (AMD).

Pegaptanib sodium, an RNA aptamer specifically targeting vascular endothelial growth factor (VEGF)-165, holds great promise for investigating neovascular age-related macular degeneration (AMD).

Lp-PLA2-IN-14 (Compound 19), an inhibitor of rhLp-PLA2, exhibits a potent inhibitory effect with a pIC50 value of 8.4. This compound is applicable in research pertaining to neurodegenerative disorders, including Alzheimer Disease (AD), glaucoma, age-related macular degeneration (AMD), and cardiovascular diseases such as atherosclerosis [1].

Lp-PLA2-IN-10 is a potent inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2), formerly known as platelet-activating factor acetylhydrolase (PAF-AH). This enzyme plays a role in the hydrolysis of lipoprotein lipids or phospholipids. The compound holds research potential for neurodegenerative diseases such as Alzheimer's disease (AD), as well as glaucoma, age-related macular degeneration (AMD), and cardiovascular diseases like atherosclerosis[1].

Lampalizumab (RG 7417), a humanized monoclonal antibody, selectively inhibits complement Factor D in the alternative complement pathway by binding to an exosite and sterically hindering Factor B's access to the active site. It is employed in the study of age-related macular degeneration (AMD) [1] [2].

Galegenimab (FHTR 2163; RG 6147; RO 7171009), an antibody fragment targeting High-temperature requirement A1 (HTRA1), is utilized in the research of age-related macular degeneration (AMD) [1].

Ranibizumab is a humanized monoclonal antibody fragment designed to target and inhibit vascular endothelial growth factor (VEGF), including VEGF110, VEGF121, and VEGF165. Ranibizumab's ability to selectively target and neutralize VEGF-A isoforms has made it a crucial component of research and treatment strategies for wet wet age-related macular degeneration (AMD).

JNJ-26076713, an orally active alpha V integrin antagonist, represents a potential therapeutic candidate for the treatment of macular edema, age-related macular degeneration, and proliferative diabetic retinopathy.

AG-13958 monohydrochloride is the HCl salt of AG-13958 --- a VEGFA inhibitor potentially for the treatment of age-related macular degeneration. Neovascular AMD, a subtype characterized by the growth of new, pathologic blood vessels, results in most of the cases of severe and rapid vision loss associated with AMD. A critical activator of angiogenesis in neovascular AMD is VEGF.

OT-551, a NF-κB inhibitor, is used potentially for the treatment of cataracts and age-related macular degeneration.

POT-4 TFA (AL-78898A TFA), a derivative of Compstatin, effectively inhibits the activation of complement factor C3. This compound is utilized in research related to age-related macular degeneration [1] [2].

ARC1905, a non-PEGylated/naked anti-C5 RNA aptamer, functions by inhibiting the cleavage of complement factor 5 (C5) into its components, C5a and C5b, without PEG conjugation. This compound is currently being researched for its potential application in the treatment of age-related macular degeneration (AMD).

Bevasiranib, a siRNA, is specifically engineered to suppress the expression of genes responsible for the production of vascular endothelial growth factor (VEGF), a critical factor in the development of choroidal neo-vascularization (CNV), which precedes wet age-related macular degeneration (wet AMD).

Norbixin, a carotenoid found in B. orellana, exhibits various biological activities including binding to the peroxisome proliferator-activated receptor γ (PPARγ) with a Ki of 1.15 µM in a cell-free assay. At a dosage of 47.7 mg/kg, norbixin effectively alleviates hyperglycemia, hyperinsulinemia, and insulin resistance, in addition to reducing serum lipid levels, cardiac thiobarbituric acid reactive substances (TBARS), and glutathione (GSH) in rat cardio-metabolic syndrome models. It also lowers serum levels of oxidized LDL, aortic protein oxidation, and the atherosclerotic area in a rabbit cholesterol-induced atherosclerosis model. Furthermore, norbixin, administered at 0.1 and 1 mg/kg per day, minimizes mercury-induced DNA damage in rat hepatocytes and leukocytes and prevents photoreceptor degeneration in an Abca4-/- Rdh8-/- mouse model of age-related macular degeneration (AMD).

Bevasiranib sodium, an siRNA compound, targets and silences the genes responsible for producing vascular endothelial growth factor (VEGF). The suppression of VEGF, a critical factor in the development of choroidal neo-vascularization (CNV), aims to thwart the progression to wet age-related macular degeneration (wet AMD).

Risuteganib hydrochloride is an anti-integrin that downregulates oxidative stress and restores homeostasis, and targets three integrin receptors that are implicated in dry age-related macular degeneration (AMD) in order to restore homeostasis in the retin

Moxaverine hydrochloride is a derivative of papaverine, a phosphodiesterase inhibitor. Moxaverine has been studied in phase III of a clinical trial for the treatment of ocular blood flow in patients with age- related macular degeneration and primary open angle glaucoma.

Lp-PLA2-IN-12 (compound 19), an Lp-PLA2 inhibitor, is utilized in researching neurodegenerative diseases including Alzheimer's disease (AD), glaucoma, age-related macular degeneration (AMD), and cardiovascular conditions such as atherosclerosis [1].

AG-13958 (AG-013958) (AG-013958), a potent VEGFR tyrosine kinase inhibitor, for the treatment of age-related macular degeneration.

Rinucumab (REGN 2176), a monoclonal antibody that acts as a PDGF inhibitor, holds potential for researching neovascular age-related macular degeneration [1].

Tarcocimab (OG1953), a humanized IgG1-type anti-VEGFA monoclonal antibody, is utilized in research targeting conditions such as retinal vein occlusion (RVO) and wet age-related macular degeneration (AMD).

ALK4290 (AKST4290) is a potent and orally actively CCR3 inhibitor, compound Example 2, with a Ki of 3.2 nM for hCCR3[1]. ALK4290 can be used for the research of neovascular age-related macular degeneration and Parkinsonism[2][3].

Fenlean (FLZ) is a tyrosine kinase Src inhibitor, a synthetic cyclic derivative of squamous amide from Annona glabra, with cytoprotective activity, which protects tyrosine hydroxylase function in a chronic MPTP/prostaglandin-type mouse model of Parkinson's disease.Fenlean inhibits the production of Aβ in the mitochondria, which may be useful in the study of age-related macular degeneration and Parkinson's disease. and Parkinson's.

TG 100801 Hydrochloride is a prodrug to treat age-related macular degeneration. TG 100572 is a inhibitor of multi-targeted kinase(IC50s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src,